Person:
KURT, MERAL

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

KURT

First Name

MERAL

Name

Search Results

Now showing 1 - 9 of 9
  • Publication
    A comparison of standard neoadjuvant long-course chemoradiotherapy and near-total neoadjuvant therapy in rectal cancer: A matched pair analysis at equal time interval
    (Elsevier Science Inc, 2022-11-01) Işık, Özlem; Çubukcu, E.; Görken, İlknur. Bilkay; Öztürk, Ersin; Terzi, Chokri; Yılmazlar, Tuncay; Kurt, Meral; KURT, MERAL; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı; AAA-3961-2020
  • Publication
    Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: Trod 01-005 study
    (Tech Science Press, 2023-01-01) Güler, Ozan Cem; Oymak, Ezgi; Yazıcı, Gözde; Akagündüz, Özlem Özkaya; Çetinayak, Oğuz; Erpolat, Petek; Aksoy, Atil; Düzova, Mürsel; Yıldırım, Berna Akkuş; Canyılmaz, Emine; Yavaş, Güler; Akyürek, Serap; Öksüz, Didem Çolpan; Sağlam, Esra Kaytan; Çelik, Ömür Karakoyun; Özyar, Enis; Cengiz, Mustafa; Önal, Cem; Kurt, Meral; KURT, MERAL; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı; 0000-0003-1637-910X; AAA-3961-2020
    The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy -confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni-and multivariable analyses. The median age of the entire cohort was 56 years (range: 26-87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients' performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78-7.00, symbolscript < 0.001) and PFS (HR = 4.28, 95% CI, 2.79-6.58, symbolscript < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12-2.98, symbolscript = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did.
  • Publication
    Improving locoregional outcome in high-intermediate-risk and high-risk stage i endometrial cancer with surgical staging followed by brachytherapy
    (Korean Soc Therapeutic Radiology & Oncology, 2022-06-01) Arslan, Sonay; Abakay, Candan Demiröz; DEMİRÖZ ABAKAY, CANDAN; Çetintaş, Sibel; ÇETİNTAŞ, SİBEL; Kurt, Meral; KURT, MERAL; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı
    Purpose: This study aims to assess the locoregional efficacy of postoperative vaginal brachytherapy (VBT) alone in patients undergoing surgical staging for early-stage high-intermediate-risk (HIR) and high-risk (HR) endometrial cancer.Materials and Methods: One hundred and four patients with early-stage HIR and HR endometrial cancer who underwent surgical staging were treated with adjuvant VBT alone. The patients with stage lb, grade I-III, stage la, grade III, lower uterine segment involvement, and lymphovascular invasion (LVI) were included to study.Results: The 5- and 10-year overall survival (OS) rates were 87% and 76%, respectively. The 5- and 10-year DFS rates were 86 0 10 and 86%, respectively. Among the patients, 92 % had endometrioid adenocarcinoma, 2% had undifferentiated carcinoma, 2 % had serous papillary carcinoma, and 4 % had clear-cell carcinoma. Of the patients, 6396 had stage lb disease, while 3796 had stage la disease. None of the patients had vaginal or pelvic lymph node recurrence, whereas two had para-aortic lymph node metastasis, one had surgical scar recurrence, one had para-aortic lymph node and brain metastasis, and one had lung metastasis. The presence of lymphatic invasion was found to be a statistically significant prognostic factor for increased distant metastasis rates (p = 0.020). Lymphatic invasion was also regarded as an independent prognostic factor for metastasis-free survival (p = 0.044).Conclusion: Our study results suggest that postoperative VBT alone is an effective and safe treatment modality with low complication in patients undergoing surgical staging for HIR and HR endometrial cancer.
  • Publication
    Dosimetric control of dose distribution calculated in computerized treatment planning system
    (Kare Publ, 2011-01-01) GÜRLER, ORHAN; Şahin, Sevim; Gürler, Orhan; Gözcü, Sema; Kurt, Meral; KURT, MERAL; Şengül, Kansu; Altay, Ali; Kahraman Çetintaş, Sibel; Özkan, Lütfi; Tıp Fakültesi; Fizik Bölümü. ; 0000-0002-9968-0119; AAB-4181-2020; ACU-4827-2022; AAH-1837-2021; AAA-3961-2020
    OBJECTIVESThe purpose of this study is providing dosimetric control by comparing dose values calculated in computerized treatment planning system (CTPS) and measured by Linear 2D-Array and ion chambers of various volumes.METHODSFields measured by Farmer, Semiflex and PinPoint ion chambers were created in CTPS. Using Linear 2D-Array, measurements were done in open, isocentric, oblique and wedge filtered fields which created in CTPS. Dose values were compared.RESULTSPinPoint ion chamber measured top dose values whereas Farmer ion chamber measured low values. The most compatible results with CTPS were obtained by Semiflex ion chamber. However, in 2D-Array measurements, concordance was observed with CTPS in central axis, difference reached 20 % in build-up and penumbra regions.CONCLUSIONThe most compatible results with CTPS were obtained by Semiflex ion chamber. Reasons of discordance in 2D-Array measurements were found as; varible dose around build-up region, and not to obtain the exact superpose of profiles' penumbra region.
  • Publication
    Gliosarcomas: Analysis of 9 cases treated with radiotherapy
    (Elsevier Ireland Ltd, 2008-09-01) Edincik, C.; Sarıhan, S.; Yıldırım, S.; Kurt, M.; Çetintaş, S.; Doğan, S.; Tolunay, S.; Edincik, C.; SARIHAN, SÜREYYA; Yıldırım, S.; KURT, MERAL; ÇETİNTAŞ, SİBEL; Doğan, Selda; TOLUNAY, ŞAHSİNE; Tıp Fakültesi; Beyin Cerrahisi Ana Bilim Dalı; 0000-0003-4816-5798; 0000-0003-2589-8585; AAA-7047-2020; AAH-4970-2021; I-7575-2015; AAI-1612-2021; AAA-3961-2020; EWI-7826-2022; EFX-2827-2022
  • Publication
    Induction chemotherapy and concomitant chemoradiotherapy (CRT) in patients with unresectable, locally advanced pancreatic carcinoma
    (Amer Soc Clinical Oncology, 2004-07-15) Kurt, Meral; Kurt, Engin; Çetintaş, Sibel; Evrensel, Türkan; Manavoğlu, Osman; Engin, Korkmazer; KURT, MERAL; Kurt, Engin; ÇETİNTAŞ, SİBEL; Evrensel, Türkan; Manavoğlu, Osman; KORKMAZ, ENGİN; Uludağ Üniversitesi; 0000-0002-9732-5340; AAA-7047-2020; AAA-3961-2020; AAJ-1027-2021; FFO-4769-2022; AAJ-1027-2021
  • Publication
    Screening for nutritional status in radiation oncology outpatients: Trod 12-01 study
    (Kare Publ, 2022-06-03) Akmansu, Muge; Kilic, Diclehan; Akyurek, Serap; Akboru, Halil; Arican Alicikus, Lutfiye Zumre; Yalman, Deniz; Yazici, Omer; Keven, Emine; Atalar, Banu; Yurut Caloglu, Vuslat; Gursel, Sukriye Bilge; Igdem, Mehmet Sefik; Kaytan Sağlam, Esra; KURT, MERAL; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı; 0000-0003-1637-910X; AAA-3961-2020
    OBJECTIVEThe objective of the study was to assess nutritional status among radiation oncology outpatients.METHODSA total of 394 consecutive oncology outpatients who were screened for nutritional status through nutritional risk screening (NRS) 2002 during their admission to 12 radiation oncology centers across Turkey in October 2018 were included in this cross-sectional screening study. Data on cancer type, time of diagnosis (former and newly diagnosed), and NRS 2002 scores were recorded. Patients with NRS 2002 scores >= 3 were considered to be at risk of malnutrition necessitating the provision of nutritional intervention. NRS 2002 scores were evaluated in the overall study population as well as according to cancer types and time of diagnosis.RESULTSNRS 2002 assessment (scores >= 3) revealed 133 (33.8%) patients to be at risk for malnutrition. The highest rates for malnutrition risk were noted for patients with lung cancer (43.8%), head-and-neck cancer (43.5%), and gastrointestinal tumors (42.7%). Poor nutritional status was evident in 36.0% and 25.3% of newly diagnosed and former cancer patients, respectively (p=0.067).CONCLUSIONThis screening study revealed malnutrition risk and need for nutritional intervention in 33.8% of cancer patients, including 36.0% of newly diagnosed patients. A need for nutritional intervention was evident in two out of every five patients with newly diagnosed cancer, emphasizing the importance of screening for nutritional risk in every cancer patient at the time of initial diagnosis given the role of appropriate multimodal nutritional intervention before anti-cancer therapy in the long-term success.
  • Publication
    An evaluation of the effects of hemoglobin levels on the efficacy of treatment and survival in patients with bladder cancer
    (Elsevier, 2004-01-01) Kurt, Meral; Canki, N; Çetintaş, SK; Saruhan, S; Yavaşcaoğlu, İsmet; Küçük, N.; Engin, K; KURT, MERAL; Canki, N.; ÇETİNTAŞ, SİBEL; Saruhan, S.; YAVAŞCAOĞLU, İSMET; Küçük, N.; Engin, K.; Tıp Fakültesi; Radyasyon Onkolojisi; 0000-0002-5139-2484; AAA-3961-2020; AAA-7047-2020; ENQ-8539-2022; DOZ-9697-2022; EIN-0828-2022; DBW-9088-2022; CQB-5826-2022
  • Publication
    Dosimetric comparison of multileaf and fixed cone collimator plans with cyberknife
    (Elsevier Ireland Ltd, 2023-05-01) Abakay, C. Demiröz; DEMİRÖZ ABAKAY, CANDAN; Kiray, Z.; Kurt, Meral; KURT, MERAL; Çetintaş, S.; ÇETİNTAŞ, SİBEL; Tıp Fakltesi; Onkoloji Ana Bilim Dalı